Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

NW Bio Refutes Latest False Headline and Attack

June 23, 2014 2:18 pm | News | Comments

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, refuted Adam Feuerstein's latest false headline and attack on the company, and reaffirmed the company's recent interim data announcements from its Phase 1/2 clinical trial of DCVax-Direct for all inoperable solid tumors. Read more...

TOPICS:

Inovio Kicks Off Study of Cervical Cancer Immunotherapy

June 23, 2014 2:13 pm | News | Comments

Inovio Pharmaceuticals Inc. announced it has initiated a Phase 1/2a clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. Read more...

TOPICS:

FDA Approves Cubist’s Skin Infection Antibiotic

June 23, 2014 2:08 pm | News | Comments

Cubist Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) approved Sivextro (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Read more...

TOPICS:
Advertisement

Shire Rejects AbbVie’s Unsolicited Offer

June 23, 2014 2:02 pm | News | Comments

Takeover target Shire highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based rival AbbVie. Read more...  

TOPICS:

Pharnext's Neuromuscular Disorder Drug Designated Orphan Drug

June 23, 2014 11:45 am | News | Comments

Pharnext SAS announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT 1A) in recognition of the value this novel oral therapeutic could bring to these patients. Read more...

TOPICS:

Novo Nordisk Posts Positive Phase 3 Data for Obesity Trial

June 23, 2014 11:39 am | News | Comments

New data from the phase 3a SCALE Obesity and Prediabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, showing that in addition to a greater body-weight loss, significantly fewer people with obesity and normal blood glucose at baseline progressed to prediabetes with liraglutide 3 mg treatment at 56 weeks, compared with placebo. Read more...

TOPICS:

BI Kicks Off Pradaxa First Ablation Trial

June 23, 2014 11:31 am | News | Comments

Boehringer Ingelheim announced the initiation of a new international study of Pradaxa (dabigatran etexilate mesylate) that will evaluate uninterrupted treatment with Pradaxa, compared to warfarin, in patients with paroxysmal or persistent non-valvular atrial fibrillation (NVAF) who are scheduled to undergo a first ablation procedure. Read more...

TOPICS:

Merck Starts Tender Offer for Idenix

June 23, 2014 11:24 am | News | Comments

Merck started a tender offer to buy all of the outstanding shares of hepatitis C treatment maker Idenix Pharmaceuticals Inc., hoping that teaming Idenix's hepatitis C medicines with its experimental drugs will produce lucrative combo therapies. Read more...

TOPICS:
Advertisement

Keeping the Lid on R&D Costs

June 23, 2014 11:14 am | by Nancy Dreyfus, Contributing Science Writer | Articles | Comments

In the past, pharmaceutical companies bolstered profits with billion-dollar blockbuster drugs that treated large populations for common conditions, but with patents running out, and development costs soaring, that business model may no longer be sustainable. Read more...

TOPICS:

Allergan Calls Valeant Bid “Grossly Inadequate”

June 23, 2014 11:03 am | News | Comments

Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate," that it is not in the best interest of Allergan's shareholders, and that shareholders should reject it. Read more...

TOPICS:

New Therapeutic Target Identified in Atherosclerosis

June 19, 2014 7:18 pm | News | Comments

A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target. Read more...

TOPICS:

Scientists Discover Molecular ‘Yin-Yang’ of Blood Vessel Growth

June 19, 2014 7:05 pm | News | Comments

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels, which could lead to new treatments for disorders involving abnormal blood vessel growth, including common disorders such as diabetic retinopathy and cancer. Read more...

TOPICS:

GlycoMimetics Kicks Off Clinical Trials of Leukemia Drug

June 19, 2014 6:58 pm | News | Comments

GlycoMimetics Inc. announced that the first healthy volunteer has been dosed in a Phase 1 clinical study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, a novel and proprietary E-selectin antagonist in the company's pipeline. Read more...

TOPICS:

Researchers Map Mouse Brain to Understand Brain Disorders

June 19, 2014 6:54 pm | News | Comments

Researchers at the Allen Institute for Brain Science have mapped the development of the mouse brain from the embryo to the adult, creating a preliminary genetic key that allows them to pinpoint the age and location of regions of the developing brain. Read more...

TOPICS:

Naloxegol Improves Opioid-Induced Constipation

June 19, 2014 6:44 pm | News | Comments

AstraZeneca announced that The New England Journal of Medicine (NEJM) has published results of two pivotal Phase 3 studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading